Panion’s shareholders benefit from CombiGene’s successful funding
Aug 24, 2018
The financing of the production development process of CombiGene’s – and therefore also Panion’s – gene therapy product is now secured, according to the press release from CombiGene on 22nd of August 2018. Read more...
Conversion of Yorkville’s convertible notes into shares
Aug 22, 2018
The Board of Directors of Panion Animal Health AB (the “Company” or “Panion”) has, pursuant to the terms and conditions of the financing arrangement between Panion and an investment fund managed by Yorkville Advisors Global (“Yorkville”) announced on 9 January 2018,...
2018 Q2 report, Period April-June
Aug 22, 2018
To the Report >>
Panion in FDA pre-submission conference
Aug 17, 2018
Panion Animal Health AB develops a unique new gene therapy treatment for dogs with drug-resistant epilepsy and the primary targeted market is the USA. The company has just been assigned to a pre-submission conference for this product with staff and experts from the...
